Miguel Soneira MD MPH

Clinical Trials

• A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) Start of enrollment: 2019 Jul 25

  Completed

  Phase 2

• A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis Start of enrollment: 2018 Oct 08

  Completed

  Phase 2

• Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus Start of enrollment: 2021 May 06

  TERMINATED

  PHASE2

• The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis Start of enrollment: 2019 Jun 25

  Recruiting

• A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis Start of enrollment: 2022 Jan 06

  Completed

  Phase 2

• Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) Start of enrollment: 2020 Jul 01

  ACTIVE_NOT_RECRUITING

  PHASE3

• Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) Start of enrollment: 2020 Jul 01

  ACTIVE_NOT_RECRUITING

  PHASE3

• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis Start of enrollment: 2019 Apr 25

  ACTIVE_NOT_RECRUITING

  PHASE4

• A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis Start of enrollment: 2022 Aug 31

  COMPLETED

  PHASE2

• A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases Start of enrollment: 2021 Jul 06

  COMPLETED

  PHASE1

• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus Start of enrollment: 2020 Aug 12

  COMPLETED

  PHASE3

• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II) Start of enrollment: 2018 Aug 02

  Completed

  Phase 3

• Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Start of enrollment: 2019 May 16

  Completed

  Phase 3

• Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) Start of enrollment: 2019 Jun 05

  Terminated

  Phase 3

• A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Start of enrollment: 2019 Apr 18

  COMPLETED

  PHASE2

• Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE Start of enrollment: 2021 Jun 03

  Completed

  Phase 1, Phase 2

• A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State Start of enrollment: 2020 Jul 27

  COMPLETED

  PHASE2

• Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus Start of enrollment: 2019 Mar 26

  COMPLETED

  PHASE2

• A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome Start of enrollment: 2019 Dec 09

  COMPLETED

  PHASE2

• A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products Start of enrollment: 2020 Apr 08

  Completed

  Phase 3

• A Study of Baricitinib in Participants With Rheumatoid Arthritis Start of enrollment: 2020 Feb 14

  Recruiting

  Phase 4

• A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Start of enrollment: 2021 Jul 12

  ACTIVE_NOT_RECRUITING

  PHASE2

• A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) Start of enrollment: 2017 Dec 22

  Completed

  Phase 2

• Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB. Start of enrollment: 2017 Jan 30

  Terminated

  Phase 1, Phase 2

• Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis Start of enrollment: 2016 Feb 25

  Completed

• A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis Start of enrollment: 2018 Feb 20

  Completed

  Phase 1, Phase 2

• Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis Start of enrollment: 2014 Mar 14

  Completed

  Phase 4

• Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease Start of enrollment: 2016 Jun 06

  Completed

  Phase 3

• Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Start of enrollment: 2017 Jul 04

  Completed

  Phase 3

• Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Start of enrollment: 2015 Jul 09

  Completed

  Phase 3

• DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] Start of enrollment: 2018 Aug 01

  ACTIVE_NOT_RECRUITING

  PHASE3

• Tritanium® Primary Acetabular Shell Study

  TERMINATED

  NA

• Trident II Tritanium Acetabular Shell Outcomes Study Start of enrollment: 2017 Jan 20

  ACTIVE_NOT_RECRUITING

  NA

• A Safety and Efficacy Study of the Birmingham Hip Resurfacing System

  ACTIVE_NOT_RECRUITING

  NA

• Join now to see all